Jump to: Authorized Access | Attribution | Authorized Requests

Study Description

Adapted from manuscript in review:

Nearly all prostate cancer deaths are from metastatic castration-resistant prostate cancer (mCRPC) but there have been few whole genome sequencing (WGS) studies of this disease state. We performed linked-read WGS on 23 mCRPC biopsy specimens and analyzed cell-free DNA sequencing data from 86 patients with mCRPC. In addition to frequent rearrangements affecting known prostate cancer genes, we observed complex rearrangements of the AR locus in most cases. These include highly recurrent tandem duplications involving an upstream enhancer of AR. A subset of cases also displayed a genome-wide tandem duplicator phenotype associated with CDK12 inactivation. Our findings highlight the complex genomic structure of mCRPC nominate new alterations that may inform prostate cancer treatment, and suggest that additional recurrent events in the noncoding mCRPC genome remain to be discovered.

Authorized Access
Publicly Available Data
  Link to other NCBI resources related to this study
Study Inclusion/Exclusion Criteria

Sequenced samples are a subset of the cohort accrued as described in Robinson et al., Cell (2015) and Armenia et al., Nature Genetics (2018, in press).

Molecular Data
TypeSourcePlatformNumber of Oligos/SNPsSNP Batch IdComment
Whole Genome Sequencing Illumina HiSeq X N/A N/A
Selected Publications
Diseases/Traits Related to Study (MeSH terms)
Links to Related Genes
Authorized Data Access Requests
See articles in PMC citing this study accession
Study Attribution
  • Principal Investigator
    • Matthew Meyerson. Dana-Farber Cancer Institute, Boston, MA, USA.